Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL).
Betty Y Chang
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Richard R. Furman
Consultant or Advisory Role - Pharmacyclics
Marc Zapatka
No relevant relationships to disclose
Jacqueline Claudia Barrientos
Research Funding - Pharmacyclics
Daniel Li
Consultant or Advisory Role - Pharmacyclics
Susanne Steggerda
Consultant or Advisory Role - Pharmacyclics
Karl Eckert
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Michelle Francesco
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Jennifer Ann Woyach
No relevant relationships to disclose
Amy J Johnson
No relevant relationships to disclose
Danelle Frances James
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Matthias Versele
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
John C. Byrd
Consultant or Advisory Role - Pharmacyclics (U)
Research Funding - Pharmacyclics
Stephan Stilgenbauer
Consultant or Advisory Role - Pharmacyclics
Honoraria - Pharmacyclics
Research Funding - Pharmacyclics
Joseph J. Buggy
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics